Literature DB >> 8107221

Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers.

J Taylor-Wiedeman1, P Sissons, J Sinclair.   

Abstract

Monocytes are one site of carriage of the human cytomegalovirus (HCMV) genome in healthy human carriers. However, as there are conflicting data detailing the level of HCMV gene expression during persistence in these cells, we have analyzed monocytes for evidence of viral immediate-early, early, and late transcription by using reverse transcription followed by PCR. We were unable to find evidence of HCMV lytic gene transcription in freshly isolated peripheral blood monocytes from HCMV-seropositive subjects. However, as differentiation of monocytes to monocyte-derived macrophages results in increased permissiveness to infection with HCMV in vitro, we examined whether such differentiation could result in reactivation of endogenous viral gene expression. Here we show that in vitro differentiation of monocytes does result in expression of endogenous HCMV immediate-early genes. Although this differentiation led to reactivation of endogenous viral immediate-early expression, we were unable to detect any early or late viral transcription. Cocultivation experiments correlated with this level of gene induction, as no productive infection was detected. These data strongly suggest a mechanism of persistence of HCMV in the peripheral blood that is independent of HCMV lytic gene expression and that initial phases of lytic gene expression in monocytes can be induced by differentiation of these cells to monocyte-derived macrophages.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107221      PMCID: PMC236617          DOI: 10.1128/JVI.68.3.1597-1604.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  The induction of gene activity in drosophilia by heat shock.

Authors:  M Ashburner; J J Bonner
Journal:  Cell       Date:  1979-06       Impact factor: 41.582

2.  Latent cytomegalovirus infection in blood donors.

Authors:  P Diosi; E Moldovan; N Tomescu
Journal:  Br Med J       Date:  1969-12-13

3.  Cytomegalovirus infection of human blood cells.

Authors:  L Einhorn; A Ost
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

4.  Structural analysis of the major immediate early gene of human cytomegalovirus.

Authors:  R M Stenberg; D R Thomsen; M F Stinski
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

5.  Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection.

Authors:  C Söderberg; S Larsson; S Bergstedt-Lindqvist; E Möller
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

6.  Nuclear RNA is spliced in the absence of poly(A) addition.

Authors:  M Zeevi; J R Nevins; J E Darnell
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

7.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

Authors:  A S Yeager; F C Grumet; E B Hafleigh; A M Arvin; J S Bradley; C G Prober
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

Review 8.  Transfusion-associated cytomegalovirus infections.

Authors:  S P Adler
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

9.  Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.

Authors:  S Tsuchiya; Y Kobayashi; Y Goto; H Okumura; S Nakae; T Konno; K Tada
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

Review 10.  Latent infection and the elusive cytomegalovirus.

Authors:  M C Jordan
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  142 in total

1.  Quantitative analysis of latent human cytomegalovirus.

Authors:  B Slobedman; E S Mocarski
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Human cytomegalovirus latency-associated protein pORF94 is dispensable for productive and latent infection.

Authors:  K L White; B Slobedman; E S Mocarski
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  The human cytomegalovirus UL82 gene product (pp71) accelerates progression through the G1 phase of the cell cycle.

Authors:  Robert F Kalejta; Thomas Shenk
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 4.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

5.  PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes.

Authors:  Gary Chan; Maciej T Nogalski; Gretchen L Bentz; M Shane Smith; Alexander Parmater; Andrew D Yurochko
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

Review 6.  Is HCMV a tumor promoter?

Authors:  Liliana Soroceanu; Charles S Cobbs
Journal:  Virus Res       Date:  2010-10-29       Impact factor: 3.303

7.  Cellular and viral control over the initial events of human cytomegalovirus experimental latency in CD34+ cells.

Authors:  Ryan T Saffert; Rhiannon R Penkert; Robert F Kalejta
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

8.  Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions.

Authors:  Sara Gredmark; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus.

Authors:  Mariana Bego; J Maciejewski; S Khaiboullina; G Pari; S St Jeor
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus.

Authors:  Alex Petrucelli; Michael Rak; Lora Grainger; Felicia Goodrum
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.